Trial Profile
A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2020
Price :
$35
*
At a glance
- Drugs MP 0250 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Molecular Partners AG
- 10 Dec 2020 Results published in the Journal of Clinical Oncology
- 05 Jun 2018 Results (n=45) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2018 According to a Molecular Partners media release, results will be presented at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO).